Prognostic value of baseline metabolic tumor volume ( MTV ) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial
European Journal of Haematology · 2023
DOI: 10.1111/ejh.14093 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Lutz van Heek und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HD17 trial was funded by the German Cancer Aid..
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
The prognostic relevance of metabolic tumor volume (MTV) having recently been demonstrated in patients with early‐stage favorable and advanced‐stage Hodgkin lymphoma. The current study aimed to assess the potential prognostic value of 18 F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) in early‐stage unfavorable Hodgkin lymphoma patients treated within the German Hodgkin Study Group HD17 trial.
Methods
18 F‐FDG PET/CT images were available for MTV analysis in 154 cases. We used three different threshold methods (SUV 2.5 , SUV 4.0 , and SUV 41% ) to calculate MTV. Receiver‐operating‐characteristic analysis was performed to describe the value of these parameters in predicting an adequate therapy response. Therapy response was evaluated as PET negativity after 2 cycles of eBEACOPP followed by 2 cycles of ABVD.
Results
All three threshold methods analyzed for MTV showed a positive correlation with the PET response after chemotherapy. Areas under the curve (AUC) were 0.70 (95% CI 0.53–0.87) and 0.65 (0.50–0.80) using the fixed thresholds of SUV 4.0 and SUV 2.5 , respectively, for MTV‐ calculation. The calculation of MTV using a relative threshold of SUV 41% showed an AUC of 0.63 (0.47–0.79).
Conclusions
MTV does have predictive value after chemotherapy in early‐stage unfavorable Hodgkin lymphoma, particularly when the fixed threshold of SUV 4.0 is used for MTV calculation.
Trial registration
ClinicalTrials.gov NCT01356680.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of C…
- Department of Radiooncology, Marienhospital Herne, Ruhr University Bochum, Bochum, Germany.
Förderung
- HD17 trial was funded by the German Cancer Aid.
Zitieren
APA
van Heek, L., Weindler, J., Gorniak, C., Kaul, H., Müller, H., Mettler, J., Baues, C., Fuchs, M., Borchmann, P., Ferdinandus, J., Dietlein, M., Voltin, C. A., Kobe, C., & Roth, K. S. (2023). Prognostic value of baseline metabolic tumor volume ( MTV ) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial. European Journal of Haematology. https://doi.org/10.1111/ejh.14093
Vancouver
van Heek L, Weindler J, Gorniak C, Kaul H, Müller H, Mettler J, et al. Prognostic value of baseline metabolic tumor volume ( MTV ) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial. European Journal of Haematology. 2023. doi:10.1111/ejh.14093
BibTeX
@article{vanHeek2023,
author = {van Heek, Lutz and Weindler, Jasmin and Gorniak, Claudia and Kaul, Helen and Müller, Horst and Mettler, Jasmin and Baues, Christian and Fuchs, Michael and Borchmann, Peter and Ferdinandus, Justin and Dietlein, Markus and Voltin, Conrad-Amadeus and Kobe, Carsten and Roth, Katrin S},
title = {Prognostic value of baseline metabolic tumor volume ( MTV ) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.14093}
}
EUVIMED